Loading…

Dietary fatty acids improve perceived sleep quality, stress, and health in migraine: a secondary analysis of a randomized controlled trial

BACKGROUND: Migraine is a prevalent disabling condition often associated with comorbid physical and psychological symptoms that contribute to impaired quality of life and disability. Studies suggest that increasing dietary omega-3 fatty acid is associated with headache reduction, but less is known a...

Full description

Bibliographic Details
Main Authors: Faurot, Keturah R., Park, Jinyoung, Miller, Vanessa, Honvoh, Gilson, Domeniciello, Anthony, Mann, J. Douglas, Gaylord, Susan A., Lynch, Chanee E., Palsson, Olafur, Ramsden, Christopher E., MacIntosh, Beth A., Horowitz, Mark, Zamora, Daisy
Format: Online Article Text
Language:English
Published: Frontiers Media S.A. 2023
Subjects:
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634433/
https://www.ncbi.nlm.nih.gov/pubmed/37954068
http://dx.doi.org/10.3389/fpain.2023.1231054
Description
Summary:BACKGROUND: Migraine is a prevalent disabling condition often associated with comorbid physical and psychological symptoms that contribute to impaired quality of life and disability. Studies suggest that increasing dietary omega-3 fatty acid is associated with headache reduction, but less is known about the effects on quality of life in migraine. METHODS: After a 4-week run-in, 182 adults with 5–20 migraine days per month were randomized to one of the 3 arms for sixteen weeks. Dietary arms included: H3L6 (a high omega-3, low omega-6 diet), H3 (a high omega-3, an average omega-6 diet), or a control diet (average intakes of omega-3 and omega-6 fatty acids). Prespecified secondary endpoints included daily diary measures (stress perception, sleep quality, and perceived health), Patient-Reported Outcome Measurement Information System Version 1.0 ([PROMIS©) measures and the Migraine Disability Assessment (MIDAS). Analyses used linear mixed effects models to control for repeated measures. RESULTS: The H3L6 diet was associated with significant improvements in stress perception [adjusted mean difference (aMD): −1.5 (95% confidence interval: −1.7 to −1.2)], sleep quality [aMD: 0.2 (95% CI:0.1–0.2)], and perceived health [aMD: 0.2 (0.2–0.3)] compared to the control. Similarly, the H3 diet was associated with significant improvements in stress perception [aMD: −0.8 (−1.1 to −0.5)], sleep quality [aMD: 0.2 (0.1, 0.3)], and perceived health [aMD: 0.3 (0.2, 0.3)] compared to the control. MIDAS scores improved substantially in the intervention groups compared with the control (H3L6 aMD: −11.8 [−25.1, 1.5] and H3 aMD: −10.7 [−24.0, 2.7]). Among the PROMIS-29 assessments, the biggest impact was on pain interference [H3L6 MD: −1.8 (−4.4, 0.7) and H3 aMD: −3.2 (−5.9, −0.5)] and pain intensity [H3L6 MD: −0.6 (−1.3, 0.1) and H3 aMD: −0.6 (−1.4, 0.1)]. DISCUSSION: The diary measures, with their increased power, supported our hypothesis that symptoms associated with migraine attacks could be responsive to specific dietary fatty acid manipulations. Changes in the PROMIS© measures reflected improvements in non-headache pain as well as physical and psychological function, largely in the expected directions. These findings suggest that increasing omega-3 with or without decreasing omega-6 in the diet may represent a reasonable adjunctive approach to reducing symptoms associated with migraine attacks. Trial Registration: ClinicalTrials.gov NCT02012790.